Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy

To evaluate the survival impact of extensive lymphadenectomy as part of debulking surgery in stage IVB ovarian cancer with supradiaphragmatic lymph node metastasis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ovarian Cancer Stage IV Adnexal Diseases Endocrine Gland Neoplasms Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Gonadal Disorders Lymph Node Metastases Lymphatic Metastasis Neoplasm Metastasis Neoplasms Neoplasms by Site Neoplastic Processes Ovarian Diseases Ovarian Neoplasms Pathologic Processes Pathological Conditions, Signs and Symptoms Urogenital Diseases Urogenital Neoplasms

Age range

18 year–90 year

Sex eligibility

Female

Study type

Observational

Primary location

Seoul National University Hospital

Seoul, 시/도/주, 03080, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Histologically diagnosed ovarian, fallopian tubal, primary peritoneal cancer
Patients suspected of metastatic lymph nodes in the cardiophrenic, internal mammary, and/or supraclavicular lymph node by CT (size larger than 5mm)
Patients clinically diagnosed FIGO stage IVB ovarian, fallopian tubal, primary peritoneal cancer
Patients underwent debulking surgery (primary debulking surgery or interval debulking surgery) at Seoul National University Hospital from January 2010 to January 2020
Patients age 18-90

Exclusion criteria

Borderline or benign ovarian disease
Patient didn't undergo debulking surgery
Non-epithelial ovarian cancer

Treatment and study plan

Debulking surgery

Procedure

debulking surgery as primary debulking surgery or interval debulking surgery

Primary outcomes

Progression-free survival

Time frame: From date of treatment until the date of first documented progression or date of death (by any cause, in the absence of disease progression) whichever came first, assessed up to 120 months

the time interval from the treatment start date to disease recurrence or progression date

Secondary outcomes

Overall survival

Time frame: From the date of treatment start date until death due to any cause, assessed up to 120 months

the time interval from the treatment start date to death or end of study date

Sponsors and collaborators

Lead sponsor

Seoul National University Hospital

Other

Registry information

Official study title

Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy on Stage IVB Ovarian Cancer With Supradiaphragmatic Lymph Node Metastasis

Acronym: SDLNOC

Important dates

Study start: 2021
Primary completion: 2021
Study completion: 2021
First posted: Aug 13, 2021
Registry last updated: Jun 26, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed